Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/182735
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Montero, Nuria | - |
dc.contributor.author | Oliveras, Laia | - |
dc.contributor.author | Soler, Maria José | - |
dc.contributor.author | Cruzado, Josep Maria | - |
dc.date.accessioned | 2022-01-27T16:49:49Z | - |
dc.date.available | 2022-01-27T16:49:49Z | - |
dc.date.issued | 2021-07-10 | - |
dc.identifier.issn | 2048-8513 | - |
dc.identifier.uri | http://hdl.handle.net/2445/182735 | - |
dc.description.abstract | Post-transplant diabetes mellitus (PTDM) is a common problem after kidney transplantation (KT), occurring in 50% of high-risk recipients. The clinical importance of PTDM lies in its impactas a significant risk factor for cardiovascular and chronic kidney disease (CKD) after solid organ transplantation. Kidney Disease: Improving Global Outcomes (KDIGO) has recently updated the treatment guidelines for diabetes management in CKD with emphasis on the newer antidiabetic agents such as dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors as add-on therapy to metformin. Given all these new diabetes treatments and the updated KDIGO guidelines, it is necessary to evaluate and give guidance on their use for DM management in KT recipients. This review summarizes the scarce published literature about the use of these new agents in the KT field. In summary, it is absolutely necessary to generate evidence in order to be able to safely use these new treatments in the KT population to improve blood glucose control, but specially to evaluate their potential cardiovascular and renal benefits that would seem to be independent of blood glucose control in PTDM patients. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Oxford University Press (OUP) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1093/ckj/sfab131 | - |
dc.relation.ispartof | Clinical Kidney Journal, 2021, vol 15, num 1, p. 5-13 | - |
dc.relation.uri | https://doi.org/10.1093/ckj/sfab131 | - |
dc.rights | cc by-nc (c) Montero, Nuria et al, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Trasplantament renal | - |
dc.subject.classification | Diabetis | - |
dc.subject.other | Kidney transplantation | - |
dc.subject.other | Diabetes | - |
dc.title | Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-01-27T08:22:36Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
sfab131.pdf | 2.18 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License